Business Wire
09 Jul 2026, 00:00 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA issued a second Complete Response Letter (CRL) to Unicycive Therapeutics. — A second CRL indicates a failure to address previous regulatory concerns, significantly delaying or jeopardizing product approval and revenue generation.
-0.80Law firm Kirby McInerney LLP is investigating Unicycive for potential violations of federal securities laws and unlawful business practices. — Legal investigations into corporate governance and securities compliance increase litigation risk and can damage investor confidence.
-0.40Which stocks this story touches
The company is facing a legal investigation into possible securities law violations and received a second FDA Complete Response Letter.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
